Between July and October 1987 an outpatient study of 191 children with acute diarrhea was undertaken in two rural communities in Mexico. Through a double-blind randomization we compared the efficacy of a combination therapy of furazolidone, 7.5 mg/kg/day, plus standard oral rehydration therapy (ORT) (96 patients) versus a placebo plus ORT (95 patients), each given for 5 days. Diarrheal stool samples were collected from all patients before therapy. By means of a two-vial transport media system the samples were sent to a university laboratory and examined for viral, bacterial, and parasitic organisms. The most commonly isolated organisms were enterotoxigenic Escherichia coli (13%) and Giardia lamblia (13%). Patients who received furazolidone plus ORT showed a greater reduction in duration of diarrhea when compared with those receiving placebo plus ORT (63.4 h versus 71.44 h). There was also a trend toward shorter duration of diarrhea in patients with Giardia who were treated with furazolidone/ORT compared with Giardia patients in the placebo/ORT group. When fecal leukocytes were present in the stool, the furazolidone/ORT-treated patients had a significantly higher percentage of clinical cures (79% versus 54%, p = 0.03) and an overall shorter duration of diarrhea (62.0 h versus 80.6 h, p = 0.055) at the end of 5 days of therapy than did the placebo/ORT-treated group.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365528909091331 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recovery time and predictors of severe acute malnutrition in children aged 6-59 months via an outpatient therapeutic program in Borena zone: A prospective cohort study.
PLoS One
January 2025
Department of Reproductive Health, College of Medical and Health Sciences, Dilla University, Dilla, Ethiopia.
Background: Severe acute malnutrition (SAM) is a severe condition causing bilateral pitting edema or signs of wasting in children, with a high mortality risk. An outpatient therapeutic program is recommended for managing SAM children without complications, but there is limited information on recovery time and its determinants.
Objective: This study aims to assess the time to recovery and its predictors among children aged 6-59 months with SAM admitted to the Outpatient therapeutic program in the Borena zone, Oromia region, Southern Ethiopia in 2023.
Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study.
Nat Commun
January 2025
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
This study (NCT04728035) aimed to explore the safety and efficacy of liposomal irinotecan (HE072) in patients with metastatic triple-negative breast cancer (mTNBC). This study consisted of two parts. In part 1, the 3 + 3 design was used to investigate three dose levels of HE072 (50, 70 and 90 mg/m).
View Article and Find Full Text PDFTen-year trends in clinical characteristics and outcome of children hospitalized with severe wasting or nutritional edema in Malawi (2011-2021): Declining admissions but worsened clinical profiles.
PLoS One
December 2024
The Childhood Acute Illness and Nutrition (CHAIN) Network, Nairobi, Kenya.
Background: Severe acute malnutrition (SAM) constitutes a substantial burden in African hospitals. Despite adhering to international guidelines, high inpatient mortality rates persist and the underlying contributing factors remain poorly understood.
Objective: We evaluated the 10-year trend (2011-2021) in clinical factors and outcomes among children with severe wasting and/or nutritional edema at Malawi's largest nutritional rehabilitation unit (NRU).
Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post-hoc analysis of imeglimin clinical trial data.
J Diabetes Investig
December 2024
Department of Medicine, Kawasaki Medical School, Okayama, Japan.
Introduction: An increased rate of gastrointestinal (GI) symptoms is reported in patients with type 2 diabetes receiving imeglimin plus metformin vs monotherapy or in combination with other antidiabetic drugs. This post-hoc analysis explored GI symptom incidence, risk factors for their occurrence, and the impact on therapeutic efficacy during imeglimin and metformin combination therapy.
Materials And Methods: Data were derived from the 52-week, open-label, phase 3 TIMES-2 trial in Japanese type 2 diabetes patients.
[Comparison of effect of different medial boundaries in laparoscopic right hemicolectomy: a meta-analysis].
Zhonghua Wei Chang Wai Ke Za Zhi
December 2024
Department of General Surgery, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou450014, China.
To investigate and compare the clinical efficacy and prognosis of D3 lymphadenectomy/complete mesocolic excision in treatment of right colon cancer with different medial boundaries. We searched The Cochrane Library, Pubmed, Embase, CBM, VIP, CNKI, and WanFang data bases for superior mesenteric artery (SMA)-oriented and superior mesenteric vein (SMV)-oriented D3 lymphadenectomy/complete mesocolic excision from inception to December, 2023. The resultant data were submitted to meta-analysis using RevMan 5.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!